8-K: Lisata Therapeutics Appoints James Nisco as Senior Vice President, Finance and Treasury and Chief Accounting Officer

Lisata Therapeutics has appointed James Nisco as its new Senior Vice President, Finance and Treasury and Chief Accounting Officer, effective April 15, 2024.

Summary

• Lisata Therapeutics has appointed James Nisco as Senior Vice President, Finance and Treasury and Chief Accounting Officer, effective April 15, 2024.
• Mr. Nisco will also serve as the company's principal financial officer and principal accounting officer.
• He has been with the company since 2012, previously holding roles such as Vice President of Finance & Treasury and Senior Director of Treasury, Financial Planning and Analysis.
• Mr. Nisco has over 25 years of experience in corporate finance, including positions at OSI Pharmaceuticals, Ciba Corporation, and Ciba-Geigy.
• His compensation includes a $350,000 annual base salary and a short-term incentive target of 35% of his base salary.

Sentiment

Score: 7

Explanation: The document reflects a routine internal promotion with clear compensation details, indicating a stable and expected transition. There are no negative aspects mentioned.

Positives

• The appointment of James Nisco provides continuity in the finance leadership, as he has been with the company since 2012.
• Mr. Nisco's extensive experience in corporate finance, spanning over 25 years, is a positive for the company.
• The compensation package, including a $350,000 base salary and a 35% bonus target, is clearly defined.

Management Comments

• The selection of Mr. Nisco to perform the functions of Senior Vice President, Finance and Treasury and Chief Accounting Officer was not pursuant to any arrangement or understanding between Mr. Nisco and any other person.

Industry Context

Executive appointments are a common occurrence in the biotech industry, and this appointment appears to be a routine internal promotion.

Comparison to Industry Standards

• The compensation package for Mr. Nisco, including a $350,000 base salary and a 35% bonus target, is within the typical range for a Senior Vice President and Chief Accounting Officer in a similar-sized biotech company.
• Comparable companies such as those in the Nasdaq Capital Market would likely have similar compensation structures for their senior finance executives.

Management Changes

Stakeholder Impact

• The appointment of a seasoned finance executive should reassure shareholders about the company's financial management.
• Employees may view this internal promotion positively, as it demonstrates career growth opportunities within the company.

Key Dates

Keywords

executive appointment, chief accounting officer, finance, treasury, financial officer, compensation, Lisata Therapeutics